Iovance (IOVA) Soars 33%, Hits All-Time High

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the 10 Stocks Investors Are Watching Closely This Week.

Iovance soared by 32.9 percent week-on-week to hit a new all-time high after an analyst doubled its price target for the stock, while investors loaded portfolios ahead of business updates next week.

In its market report, investment firm UBS raised its price target for Iovance Biotherapeutics Inc. (NASDAQ:IOVA) to $4 from $2 previously, but maintained a “neutral” stance on its stock.

Photo from Iovance Biotherapeutics website

The coverage came ahead of the biopharmaceutical firm’s participation in Barclays’ 28th Annual Global Healthcare Conference on Wednesday, March 11, where investors will watch out for cues and company developments to support buying appetite.

In other news, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) recently reported a 5 percent wider net loss last year, at $390.98 million versus $372 million in 2024. Total revenues, on the other hand, jumped by 60.6 percent to $263.5 million from $164.07 million year-on-year.

In the fourth quarter alone, net loss narrowed by 8 percent to $71.9 million from the $78.5 million in the same period a year earlier, while revenues increased by 17.6 percent to $86.7 million from $73.69 million year-on-year.

While we acknowledge the potential of IOVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.